系统性IFN-I与局部TLR7/8激动剂相结合,通过c-Jun依赖IL-12表达在树突细胞中促进远程瘤抑制
Martina Sanlorenzo1, Philipp Novoszel1, Igor Vujic2
1Center for Cancer Research, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Nature cancer
|January 23, 2025
概括
托尔类受体7/8激动剂伊米基莫德 (IMQ) 通过激活树突细胞 (DCs) 有效地治疗瘤和转移. 系统和局部IMQ,结合干扰素I和PD-1阻断,增强抗瘤免疫力和记忆反应.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 树突细胞生物学 树突细胞生物学
背景情况:
- 通过模式识别受体 (如Toll-like受体 (TLRs)) 激活树突细胞 (DC) 对于有效的癌症免疫治疗至关重要.
- 伊米基莫德 (IMQ) 是TLR7/8激动剂,在治疗各种癌症方面表现有前途.
研究的目的:
- 研究IMQ在治疗局部瘤和远程转移中的疗效.
- 阐明IMQ介导的抗瘤免疫的潜在机制.
- 探索组合策略,以提高治疗结果.
主要方法:
- 口服和局部使用IMQ.
- 对直流激活,I型干扰素 (IFN-I) 生产和TLR7/8表达的评估.
- 对化学激素 (CCL2) 和细胞激素 (介质素-12,VEGF-A) 水平的分析.
- 评估CD8+T细胞的反应和记忆的形成.
- 与来自黑色素瘤队列的患者数据的相关性.
主要成果:
- 口服IMQ激活血类DCs (pDCs),诱导全身IFN-I的产生.
- IFN-I为增强的TLR7/8信号提供DC和巨细胞,这对于局部IMQ疗效至关重要.
- 治疗IMQ可以调节CCL2和互白素-12,抑制瘤血管生成 (VEGF-A) 和促进缩.
- 组合疗法 (IMQ/IFN-I与PD-1阻断) 诱导强大的CD8+T细胞依赖的抗转移反应和长期记忆.
- 患者数据证实IFN-I诱导的TLR7/8在DC上调.
结论:
- 系统和局部IMQ的管理提供了癌症治疗的双重方法.
- 该机制涉及IFN-I介导的DCs初始化,导致增强的抗瘤免疫力.
- 组合疗法具有显著的转化潜力,可以改善局部可访问瘤的免疫治疗结果.
更多相关视频
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
8.9K
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
11.3K
相关概念视频
Tumor Immunotherapy
467
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
467
T Cell Types and Functions
945
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
945
Cytotoxic T Cells-mediated Immune Response
836
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
836
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
